Zacks Investment Research·4 days ago
Should You Continue to Hold ILMN Stock in Your Portfolio?Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.
Illumina, Inc.(ILMN)Earnings, Financials & Key Ratios
ILMN•NASDAQ
$191.76
35.2× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryLife Science Instruments and Sequencing Tools
AboutIllumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.Show more
- Revenue$4.34B-0.8%
- EBITDA$1.13B+336.7%
- Net Income$850M+169.5%
- EPS (Diluted)5.45+170.9%
- Gross Margin66.69%+1.9%
- EBITDA Margin26.14%+338.6%
- Operating Margin19.92%+204.5%
- Net Margin19.59%+170.0%
- ROE33.36%+210.7%
ILMN Price & Volume
Illumina, Inc. (ILMN) stock price & volume — 10-year historical chart
Loading chart...
Illumina Navigates Operational Restructuring Amid Margin Recovery
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Adequate
Cash Flow:Improving
Primary Risk:Divestiture execution and competition
Key Thesis Takeaways
- Illumina is currently transitioning toward a leaner operational profile following the divestiture of GRAIL, which has allowed the company to stabilize its balance sheet and improve core profitability.
- While top-line growth remains stagnant with recent quarterly fluctuations between -4.9% and 5.1%, the company's focus on cost discipline has successfully reduced SG&A expenses from $485 million in 2023Q4 to $272 million in 2026Q1.
- Investors should monitor the sustainability of this margin expansion and the company's ability to regain consistent revenue growth in the competitive high-throughput sequencing market.
Verdict Logic
while the company has successfully improved its free cash flow margin to 23.0% and deleveraged its balance sheet, the stagnant revenue growth and high forward P/E of 33.74 suggest that the market has already priced in much of the operational turnaround.
ILMN Growth Metrics
Illumina, Inc. (ILMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.93%
5 Years6.02%
3 Years-1.82%
TTM1.25%
Profit CAGR
10 Years6.3%
5 Years5.32%
3 Years-
TTM188.39%
EPS CAGR
10 Years5.8%
5 Years4.23%
3 Years-
TTM190.33%
Return on Capital
10 Years3.31%
5 Years-8.68%
3 Years-2.26%
Last Year17.61%
ILMN Recent Earnings
Illumina, Inc. (ILMN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.15+9.5%
$1.05
Rev
$1.1B+1.7%
$1.1B
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.35+8.9%
$1.24
Rev
$1.2B+3.6%
$1.1B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.34+14.5%
$1.17
Rev
$1.1B+1.6%
$1.1B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$1.19+16.7%
$1.02
Rev
$1.1B-0.6%
$1.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.15vs $1.05+9.5% | $1.1Bvs $1.1B+1.7% |
| Q1 2026 | Feb 5, 2026 | $1.35vs $1.24+8.9% | $1.2Bvs $1.1B+3.6% |
| Q4 2025 | Oct 30, 2025 | $1.34vs $1.17+14.5% | $1.1Bvs $1.1B+1.6% |
| Q3 2025 | Jul 31, 2025 | $1.19vs $1.02+16.7% | $1.1Bvs $1.1B-0.6% |
Based on last 12 quarters of dataView full earnings history →
Latest ILMN News
Recent stock market news and headlines for Illumina, Inc. (ILMN)
Zacks Investment Research·6 days ago
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Zacks Investment Research·Jun 29, 2026
Here's Why Illumina (ILMN) is a Strong Growth StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reuters·Jun 29, 2026
Roche launches Axelios gene sequencer in a bid to loosen Illumina's gripSwiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
PRNewsWire·Jun 23, 2026
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of DirectorsEli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.
Peers Comparison
Key metrics vs top competitors for Illumina, Inc. (ILMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $191.76 | $29.13B | 35.19 | -0.78% | 19.59% | 33.36% | — | |
| $1.56 | $484.54M | -0.86 | 3.89% | -80.34% | -488.45% | — | |
| $58.25 | $8.87B | -388.33 | 2.08% | -0.34% | -0.5% | — | |
| $516.62 | $191.99B | 29.12 | 3.91% | 15.18% | 13.23% | — | |
| $194.19 | $137.44B | 38.53 | 2.9% | 14.89% | 7.06% | — | |
| $131.14 | $37.04B | 28.70 | 6.73% | 19.55% | 20.84% | — |
Compare ILMN vs Peers
Illumina, Inc. (ILMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ILMN SEC Filings & Documents
Illumina, Inc. (ILMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Feb 5, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when ILMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ILMN Frequently Asked Questions
Illumina, Inc. (ILMN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Illumina, Inc.'s revenue?
Illumina, Inc. (ILMN) reported $4.39B in revenue for fiscal year 2025. This represents a 926220% increase from $0.5M in 1999.
How fast is Illumina, Inc. growing?
Illumina, Inc. (ILMN) saw revenue decline by 0.8% over the past year.
Is ILMN profitable?
Yes, Illumina, Inc. (ILMN) is profitable, generating $853.0M in net income for fiscal year 2025 (19.6% net margin).
Dividend & Returns
What is ILMN's return on equity?
Illumina, Inc. (ILMN) has a return on equity (ROE) of 33.4%. This is excellent, indicating efficient use of shareholder capital.
What is Illumina, Inc.'s free cash flow?
Illumina, Inc. (ILMN) generated $989.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.